Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3787-3792

  Katoh, R ^a   Takenoshita, S ^a   Shimizu, Y ^b   Tanaka, S ^a   Yajima, Y ^a   Nagamachi, Y ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Gunma Cancer Center   (Japan)

Author keywords

BRM; Chemotherapy; IAP; Lung cancer; sIL 2R

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE ACID PROTEIN; INTERLEUKIN 2 RECEPTOR; POLYSACCHARIDE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MALE; PRIORITY JOURNAL; RELAPSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; CARBOPLATIN; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOGLYCANS; RECEPTORS, INTERLEUKIN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0031452313     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Asano S and Ono M: Human granulocyte colony-stimulating factor: Its biological action and clinical implication. Acta Hematol Jpn 50: 106-112, 1987.
2. Yamaguchi T, Kurita Y, Saito R et al: Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy in small-cell lung cancer. Biotherapy 8: 1423-1424, 1994.
3. Sakagami H, Aoki T, Albert Simpson et al: Induction of immunopotentiation activity by a protein-bound polysaccharide, PSK (Review). Anticancer Res 11: 993-1000, 1991.
4. Nakazato H, Koike A, Saji S et al: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer The Lancet 343: 1823-, 1994.
5. Hayakawa K, Mithuhashi N, Saito Y et al: Effect of krestin (PSK) as adjuvant treatment of the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 13: 1815-1820, 1993.
6. Lotze MT, Custer MC, Sharrow SO et al: In vivo administration of purified IL-2 to patients with cancer: development of IL-2 receptor following IL-2 administration. Cancer Res 47: 2188-2195, 1987.
7. Gooding R, Riches P, Dadian G et al: Increased soluble IL-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer 72: 452-455, 1995.
8. Tamura K et al: Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients Cancer Res 41: 3244-3262, 1981.
9. Aso H et al: Impaired NK response of cancer patients to IFN but not to IL-2: correlation with serum immunosuppressive acidic protein CAP) and role of suppressor macrophage. Microbiol Immunol 36: 1087-1097, 1992.